The recommended starting dose is 50mg capsule taken orally once daily on a 4 weeks on/ 2 weeks off dosing schedule1.
Treatment with SUTENT should be continued if the patient is deriving clinical benefit from therapy.
SUTENT is for oral administration. It may be taken with or without food. If a dose is missed, the patient should not be given an additional dose. The patient should take the usual prescribed dose on the following day.1
SUTENT is available in 3 doses to facilitate dose modification in steps of 12.5mg.
Recommended Starting Dose |
50 mg |
|---|---|
1st Dose Reduction |
37.5 mg |
2nd Dose Reduction |
25 mg |
3rd Dose Reduction |
12.5 mg |
For GIST and mRCC, dose modifications in 12.5 mg steps may be applied based on individual safety and tolerability. Daily dose should not exceed 75 mg nor be decreased below 25 mg.
For pNET, the recommended dose of Sutent is 37.5 mg taken orally once daily without a scheduled rest period, dose modifications in 12.5mg steps may be applied base on individual safety and tolerability.
For GIST and mRCC only
Negrier S. Oncology 2012;82:189-196
Castellano D, et al. Cancer Treat Rev 2013;39:230-240
SUTENT Summary of Product Characteristics
As with all medications, SUTENT interact with certain drugs. Please refer to the
SUTENT® Summary of Product Characteristics for Great Britain or the SUTENT® Summary of Product Characteristics for Northern Ireland for a complete list of drug-drug interactions.
AE : Adverse Event
GIST: Gastrointestinal Stromal Tumour
mRCC: Metastatic Renal Cell Carcinoma
pNET: Pancreatic Neuroendocrine Tumour
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021